G Mazziotti
Overview
Explore the profile of G Mazziotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cianferotti L, Cipriani C, Palermo A, Viapiana O, Zavatta G, Mazziotti G
J Endocrinol Invest
. 2024 May;
47(11):2649-2662.
PMID: 38789679
Background: Romosozumab, a fully humanized anti-sclerostin-antibody, is a bone-builder stimulating osteoblasts and inhibiting osteoclast by activation of the canonical Wnt-beta catenin signaling. This unique mechanism of action has the potential...
2.
Cremaschi A, Sala E, Lavezzi E, Carosi G, Del Sindaco G, Mangone A, et al.
J Endocrinol Invest
. 2024 Mar;
47(9):2269-2277.
PMID: 38502285
Background: Recurrence of acromegaly after successful surgery is a rare event, but no clear data are reported in the literature about its recurrence rates. This study aimed to evaluate the...
3.
Vitali E, Grasso A, Schiavone M, Trivellin G, Sobacchi C, Mione M, et al.
J Endocrinol Invest
. 2023 Dec;
47(6):1385-1394.
PMID: 38159174
Purpose: Acromegaly is a chronic disease characterized by growth hormone (GH) hypersecretion, usually caused by a pituitary adenoma, resulting in elevated circulating levels of insulin-like growth factor type I (IGF-I)....
4.
Mazziotti G, Lania A, Lagana M, Berruti A
Endocrine
. 2023 Dec;
83(3):594-596.
PMID: 38112923
Bone fragility in men who are treated with androgen deprivation therapy (ADT) has a complex pathophysiology that differs from that of primary and post-menopausal osteoporosis. Fracture risk assessment based on...
5.
Vitali E, Valente G, Panzardi A, Laffi A, Zerbi A, Uccella S, et al.
J Endocrinol Invest
. 2023 Oct;
47(5):1101-1117.
PMID: 37882947
Purpose: The finding of mTOR overactivation in patients affected by pancreatic neuroendocrine tumors (Pa-NETs) led to their treatment with the mTOR inhibitor everolimus. Unfortunately, the efficacy of everolimus is restricted...
6.
Antonini S, Pedersini R, Birtolo M, Baruch N, Carrone F, Jaafar S, et al.
J Endocrinol Invest
. 2023 Oct;
47(3):759.
PMID: 37814065
No abstract available.
7.
Antonini S, Pedersini R, Birtolo M, Baruch N, Carrone F, Jaafar S, et al.
J Endocrinol Invest
. 2023 Aug;
47(2):433-442.
PMID: 37592052
Purpose: Trabecular bone score (TBS) is a gray-level textural metric that has shown to correlate with risk of fractures in several forms of osteoporosis. The value of TBS in predicting...
8.
Dalla Volta A, Palumbo C, Zamboni S, Mazziotti G, Triggiani L, Zamparini M, et al.
J Endocrinol Invest
. 2023 Jul;
47(2):335-343.
PMID: 37458931
Background: It is not clear whether changes in body composition induced by androgen deprivation therapy (ADT) in prostate cancer (PC) patients are uniform or vary in the different body districts...
9.
Birtolo M, Grossrubatscher E, Antonini S, Loli P, Mazziotti G, Lania A, et al.
J Endocrinol Invest
. 2023 May;
46(10):1983-1994.
PMID: 37195583
Purpose: ACTH-secreting pheochromocytoma is a rare cause of ectopic Cushing's syndrome, posing a clinical challenge for the severity of its clinical presentation, the difficulty in the prevention and the management...
10.
Cianferotti L, Cipriani C, Corbetta S, Corona G, Defeudis G, Lania A, et al.
J Endocrinol Invest
. 2023 Mar;
46(7):1283-1304.
PMID: 36918505
Purpose: Bone is one of the main targets of hormones and endocrine diseases are frequent causes of secondary osteoporosis and fractures in real-world clinical practice. However, diagnosis of skeletal fragility...